Search

Objective: To evaluate the efficacy and safety of percutaneous microwave ablation (PMWA) for treating adenomyosis in the posterior uterine wall. Methods: Thirty‐six patients with symptomatic adenomyosis in the posterior uterine wall who had been subjected to PMWA were retrospectively enrolled in this study. 20 patients who had no ideal transabdominal puncture path due to the retroverted or retroflexed uterine position were treated with PMWA combined with Yu's uteropexy (Group 1). The other 16 patients were treated with PMWA only (Group 2). The non‐perfused volume (NPV) ratio, symptomatic relief rate, recurrence rate, changes in clinical symptom scores, economic cost, and complications were compared. Results: The mean NPV ratio for the 36 patients was 90.2±18.3%, and the percentage of patients who obtained complete relief of dysmenorrhea and menorrhagia was 81.3% (26/32), and 69.6% (16/23) respectively. The recurrence rate was 11.1% (4/36). No major complication was observed. Minor complications included lower abdominal pain, fever, vaginal discharge, nausea, and/or vomiting after ablation, with incidences of 55.6%, 41.7%, 47.2%, and 19.4% respectively. Subgroup analysis showed no significant difference in the median value of NPV ratio, symptomatic relief rate of dysmenorrhea and menorrhagia, changes in clinical symptom scores, recurrence rate and economic cost between the two groups (all p > 0.05). Conclusion: PMWA is an effective and safe treatment for adenomyosis in the posterior uterine wall. Advances in knowledge: This study focused on the ultrasound‐guided PMWA treatment for adenomyosis in the posterior uterine wall. Yu's uteropexy, a new ancillary technique allowing safe PMWA for deep posterior uterine wall lesions in retroverted uterus, expanded the indications of PMWA for symptomatic adenomyosis. [ABSTRACT FROM AUTHOR]

The article discusses the study that aims to evaluate the value of fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment contrast-enhanced computed tomography/magnetic resonance imaging in evaluating the ablative safety margin after percutaneous ultrasound guided radiofrequency ablation (RFA) for liver cancers. It states that all methods are effective in evaluating the ablative safety margin early after RFA.

Objective: To assess the added value of contrast‐enhanced ultrasound (CEUS) to conventional ultrasound in differentiating benign soft‐tissue tumors from malignant ones. Methods: 197 soft‐tissue tumors underwent ultrasound examination with confirmed histopathology were retrospectively evaluated. The radiologists classified all the tumors as benign, malignant, or indeterminate according to ultrasound features. The indeterminate tumors underwent CEUS were reviewed afterwards for malignancy identification by using individual and combined CEUS features. Results: Ultrasound analysis classified 62 soft‐tissue tumors as benign, 111 tumors as indeterminate and 24 tumors as malignant. There 104 indeterminate tumors were subject to CEUS. Three CEUS features including enlargement of enhancement area, infiltrative enhancement boundary, and intratumoral arrival time difference were significantly associated with the tumor nature in both univariable and multivariable analysis for the indeterminate tumors (all p < 0.05). When at least one out of the three discriminant CEUS features were present, the best sensitivity of 100% for malignancy identification was obtained with the specificity of 66.7% and the AUC of 0.833. When at least two of the three discriminant CEUS features were present, the best area under the receiver operating characteristic curve (AUC) of 0.924 for malignancy identification was obtained. The combination of at least two discriminant CEUS features showed much better diagnostic performance than the optimal combination of ultrasound features in terms of AUC (0.924 vs 0.608, p < 0.0001), sensitivity (94.0% vs 42.0%, p < 0.0001), and specificity (90.7% vs 79.6%, p = 0.210) for the indeterminate tumors. Conclusion: The combination CEUS features of enlargement of enhancement area, infiltrative enhancement boundary and intratumoral arrival time difference are valuable to improve the discriminating performance for indeterminate soft‐tissue tumors on conventional ultrasound. Advances in knowledge: The combination of peritumoral and arrival‐time CEUS features can improve the discriminating performance for indeterminate soft‐tissue tumors on conventional ultrasound. [ABSTRACT FROM AUTHOR]

Objective: To investigate the mid‐term local treatment efficiency of ultrasound‐guided percutaneous microwave ablation (MWA) for uterine fibroids (UFs) and the associated influencing factors. Methods: From July 2020 to October 2021, a total of 28 patients with 52 UFs who had undergone ultrasound‐guided MWA were retrospectively included in this study. Pre‐treatment clinical characteristics, conventional ultrasound and contrast‐enhanced ultrasound (CEUS) features were analyzed to explore their correlation with volume reduction ratios (VRRs) of sufficient ablation (i.e. a VRR of at least 50% at the 3 month follow‐up). The patients were assessed at 1‐, 3‐, 6 month follow‐up after MWA treatment and the assessment included VRR, adverse events, uterine fibroid symptom (UFS) and quality of life (QoL) scores, and clinical symptoms. Results: The procedures of percutaneous MWA for UFs were tolerated well and no major complications occurred in all patients. At the 1‐, 3‐, 6 month follow‐up, the median VRRs of UFs were 30.1%, 46.9%, and 65.8%, respectively. At the 3 month follow‐up, 44.4% of fibroids obtained sufficient ablation while the remaining 55.6% obtained partial ablation (i.e. a VRR of <50%). Non‐enhancing area during the early phase (i.e. within 30 s after injecting contrast agent) on pre‐treatment CEUS was present in 22.2% UFs, which was associated with sufficient ablation at the 3 month follow‐up (p < 0.05). In addition, the relevant clinical symptoms of all patients were alleviated or removed. The UFS and QoL score after MWA decreased significantly in comparison with those after MWA (p = 0.04 and p = 0.057, respectively), indicating a remarkable improvement of clinical symptom and QoL. Conclusion: Ultrasound‐guided MWA is an effective and safe method to treat patients with UFs. Non‐enhancing area during the early phase on pretreatment CEUS is associated with mid‐term local treatment efficiency, which might be used to predict treatment outcome. Advances in knowledge: Non‐enhancing area during the early phase on pretreatment CEUS is an important factor associated with mid‐term local treatment efficiency. This is the first study finding that CEUS feature can be used as a marker for the prediction of mid‐term local treatment response. [ABSTRACT FROM AUTHOR]

The article focuses on a study which seeks to examine the therapeutic efficacy as well as safety of ultrasound-guided percutaneous bipolar radiofrequency ablation (BRFA) of benign thyroid nodules by comparison with a matched untreated control group. An overview of thyroid nodules and the application of RFA is presented.

The aim of this study was to develop an ultrasound consolidated score (UCS) in determining the activity of Crohn's disease (CD) and evaluate it with reference to simple endoscopic score (SES). From June 2014 to June 2017, 66 patients with CD were retrospectively enrolled in this study. Each patient underwent endoscopy and transabdominal ultrasound (US) examination. The morphological symmetry, echogenicity of bowel wall, bowel wall layer structure, echogenicity of peri-bowel fat, bowel wall thickness (BWT), and Limberg type on power Doppler US were assessed with transabdominal US, and an UCS scoring system was developed based on these characteristics. Endoscopic results were used as the reference standard and SES was calculated to determine the CD activity. Receiver operating characteristic curve analysis was performed to assess the diagnostic performance for determining CD activity and the correlation between UCS and SES was assessed using Spearman correlation analysis. 330 intestinal segments in 66 patients were included. The UCS of the segments in the remission phase ranged from 3.0 to 9.0 (mean, 3.6 ± 0.9) whereas in the active phase from 3.0 to 20.0 (mean, 10.6 ± 4.0) (p < 0.001). The cut-off value of UCS was 6. The associated area under ROC curve, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 0.980, 88.3%, 95.5%, 93.8%, 91.3%, and 92.3%, respectively. The correlation coefficient between UCS and SES was 0.90, which was higher than the correlation coefficient of 0.83 between BWT and SES. The newly developed UCS with transabdominal US has a good performance and potentially provides an effective alternative for evaluating the activity of CD. UCS is an effective method to evaluate the activity of CD because it provides comprehensive information of the disease. Therefore, it could be employed as an alternative for diagnosis of CD. [ABSTRACT FROM AUTHOR]